Clinical Pathway for Alzheimer's Disease in China (CPAD)

Outpatients who are visiting memory clinics and who are judged by physicians with clinically significant cognitive impairment will be invited to join the study during the study recruiting period (with informed consent signed).

• Patients enrolled into the study will be evaluated and diagnosed by participating physicians and may or may not be prescribed with therapy (pharmaceutical and/or non-pharmaceutical) based on physicians' medical judgment.
• For patients with routine clinical follow-up visits, their medical charts will be reviewed for documentation. The procedures of making diagnosis and developing treatment scheme will be retrieved and documented in clinical report form (CRF). Additional procedures ordered by the participating physician at current visits will also be documented in CRF.

All participants will be followed twice after baseline visit to re-evaluate and confirm the initial diagnosis (where applicable), and to record compliance to treatment scheme, including the process of medication titration.

This study does not recommend nor restrict any specific treatments.

Inclusion criteria

• Male and female outpatients with clinically significant cognitive impairment per independent judgment of participating physicians;
• Aged 45 year old and above;
• Willing to receive 2 follow-up visits;
• Having at least one informant or caregiver accompanying during each visit;
• Willing to join the study and sign the informed consent prior to the study.

Exclusion criteria

• Cognitive impairment is likely or identified as secondary to other disease condition(s) than AD (including but not limited to stroke, Parkinson's disease, brain trauma, central nervous system infection, etc.)
• Unwilling to participate in the study;
• Participating other studies during the registry study period.